【摘要】：目的：心房顫動(房顫)是最常見的心律失常,如發(fā)生在無器質性心臟病變者,則稱為孤立性房顫,其相關研究較少。臨床檢查雖未見明顯的心臟結構及運動異常,但可能已經(jīng)存在輕微的結構和功能改變。MicroRNA-21 (miRNA-21)是新近發(fā)現(xiàn)的與心臟結構重構密切相關的小分子RNA。目前孤立性房顫與血漿miRNA-21水平關系的研究尚未見報道。本實驗旨在通過研究孤立性房顫患者血漿miRNA-21水平,初步探討血漿miRNA-21與孤立性房顫的相關性,闡述miRNA-21在孤立性房顫診斷中的價值。方法：連續(xù)收集2013年6月至2015年1月于我院心內(nèi)科確診為孤立性房顫,其中孤立性房顫組又分成陣發(fā)性房顫、持續(xù)性房顫兩個亞組。健康對照組23例為來自門診體檢的健康人。所有患者均于清晨空腹靜息狀態(tài)下,肘靜脈抽血后,提取血漿總RNA,質量鑒定后,進行逆轉錄,qRT-PCR技術測量血漿miRNA-21的水平。數(shù)據(jù)統(tǒng)計學分析采用SPSS18.0軟件進行。結果：1、健康對照組血漿miRNA-21相對表達量(2-△△Ct)為1.13±0.57,而孤立性房顫組血漿miRNA-21相對表達量為1.88±0.77,差異有統(tǒng)計學意義(P0.01)；2、陣發(fā)性房顫和持續(xù)性房顫兩個亞組,血漿miRNA-21相對表達量分別為1.49±0.61和2.19±0.76。其中陣發(fā)性房顫組miRNA-21較健康對照組有略微升高趨勢,但無統(tǒng)計學意義(P0.05)；而持續(xù)房顫組miRNA-21明顯高于健康對照組,差異有統(tǒng)計學意義(P0.001)；而且也高于陣發(fā)性房顫組,差異具有統(tǒng)計學意義(P0.01)結論：1、孤立性房顫血漿miRNA-21表達量較健康對照組明顯升高,提示miRNA-21可能參與房顫的發(fā)生和維持,孤立性房顫存在心房結構重構；2、持續(xù)性房顫患者血漿miRNA-21表達量明顯高于健康對照及陣發(fā)性房顫患者,‘而陣發(fā)性房顫miRNA-21表達相對于健康對照組無明顯升高,提示miRNA-21的表達可能跟房顫發(fā)作的嚴重程度密切相關；3、miRNA-21可用作評價孤立性房顫病情嚴重程度及預后的客觀生物標志物。
[Abstract]:Objective: atrial fibrillation (AF) is the most common arrhythmia. Although there is no obvious abnormality of cardiac structure and movement in clinical examination, there may already be slight structural and functional changes. MicroRNA-21 (miRNA-21) is a newly discovered small molecule RNA which is closely related to cardiac structural remodeling. The relationship between isolated atrial fibrillation and plasma miRNA-21 levels has not been reported. The aim of this study was to study the level of miRNA-21 in plasma of patients with isolated atrial fibrillation, and to explore the relationship between miRNA-21 and isolated atrial fibrillation, and to elucidate the value of miRNA-21 in the diagnosis of isolated atrial fibrillation. Methods: isolated atrial fibrillation was diagnosed in our hospital from June 2013 to January 2015. The isolated atrial fibrillation group was divided into two subgroups: paroxysmal atrial fibrillation and persistent atrial fibrillation. The healthy control group consisted of 23 healthy persons from outpatient examination. Plasma total RNAs were extracted from all patients at fasting resting state in the morning after cubital vein blood sampling. After quality identification, the level of miRNA-21 in plasma was measured by reverse transcription qRT-PCR. The data were analyzed by SPSS 18.0 software. Results the relative expression of miRNA-21 was 1.13 鹵0.57 in healthy control group and 1.88 鹵0.77 in isolated atrial fibrillation group. The difference was statistically significant (P0.01). There were two subgroups of paroxysmal atrial fibrillation and persistent atrial fibrillation. The relative expression levels of miRNA-21 in plasma were 1.49 鹵0.61 and 2.19 鹵0.76, respectively. The miRNA-21 in paroxysmal atrial fibrillation group was slightly higher than that in the healthy control group, but had no statistical significance (P0.05), while the miRNA-21 level in the persistent atrial fibrillation group was significantly higher than that in the healthy control group (P0.001), and was also higher than that in the paroxysmal atrial fibrillation group. The difference was statistically significant (P0.01). Conclusion the expression of miRNA-21 in isolated atrial fibrillation plasma is significantly higher than that in healthy control group (P0.01), suggesting that miRNA-21 may be involved in the occurrence and maintenance of atrial fibrillation, and isolated atrial fibrillation has atrial structural remodeling. 2. The expression of miRNA-21 in patients with persistent atrial fibrillation was significantly higher than that in healthy controls and patients with paroxysmal atrial fibrillation, but the expression of miRNA-21 in patients with paroxysmal atrial fibrillation was not significantly higher than that in healthy controls. It is suggested that miRNA-21 expression may be closely related to the severity of atrial fibrillation attack. MiRNA-21 may be used as an objective biomarker for evaluating the severity and prognosis of isolated atrial fibrillation.
【學位授予單位】：福建中醫(yī)藥大學
【學位級別】：碩士
【學位授予年份】：2015
【分類號】：R541.75

【相似文獻】

相關期刊論文 前10條

1 周琪;張萍;郭繼鴻;;孤立性房顫的臨床特征及亞型分析[J];臨床心電學雜志;2007年02期

2 賈志豪;;老齡孤立性房顫30年隨訪研究結果[J];中國心血管病研究;2007年10期

3 袁志敏;;增齡相關孤立性房顫遠期進展及預后分析[J];國外醫(yī)學(老年醫(yī)學分冊);2008年06期

4 段言峰;邢晨芳;謝建雄;;應變率成像定量評價孤立性房顫患者局部左房功能的研究[J];現(xiàn)代醫(yī)用影像學;2010年06期

5 安萍;;孤立性房顫與炎癥的關系[J];求醫(yī)問藥(下半月);2012年06期

6 王曹鋒;孤立性房顫:陣發(fā)型與慢性型10年隨訪后的預后差異[J];國外醫(yī)學.心血管疾病分冊;2000年01期

7 查濱;關偉華;張麗;;高血壓房顫與孤立性房顫的臨床對比分析[J];現(xiàn)代生物醫(yī)學進展;2006年10期

8 Jahangir A.;Lee V.;Friedman P.A.;杜媛;;孤立性房顫患者增齡性長期進展和預后:一項30年隨訪研究[J];世界核心醫(yī)學期刊文摘(心臟病學分冊);2007年10期

9 何斌;楊午鳴;;關于孤立性房顫非疾病誘發(fā)因素的分析[J];浙江中醫(yī)藥大學學報;2010年05期

10 常陽，郭榮利，，臧雅萍;家族性孤立性房顫3例[J];遼寧醫(yī)學雜志;1996年01期

相關會議論文 前2條

1 梅舉;馬南;姜兆磊;;微創(chuàng)外科治療孤立性房顫的臨床研究(附100例中期結果)[A];中華醫(yī)學會第十五次全國心血管病學大會論文匯編[C];2013年

2 梅舉;馬南;丁芳寶;肖海波;胡豐慶;;單側胸壁徑路超微創(chuàng)外科治療孤立性房顫的研究[A];中國心臟大會（CHC）2011暨北京國際心血管病論壇論文集[C];2011年

相關重要報紙文章 前5條

1 本報記者 馬艷紅;微創(chuàng)消融拓展房顫外科治療范疇[N];中國醫(yī)藥報;2007年

2 副主任醫(yī)師 楊鋒;當心房顫潛藏殺機[N];家庭醫(yī)生報;2003年

3 胡大一;觀不適 識房顫[N];健康報;2006年

4 湖南 教授 羅學宏;當心房顫成為健康“殺手”[N];家庭醫(yī)生報;2009年

5 駐京記者 賈巖;房顫須積極抗栓防卒中[N];醫(yī)藥經(jīng)濟報;2011年

相關碩士學位論文 前5條

1 劉莉紅;超聲新技術評價高血壓房顫及孤立性房顫患者左心功能[D];大連醫(yī)科大學;2013年

2 豐明俊;孤立性心房顫動患者KCNQ1及KCNJ2基因變異研究[D];寧波大學;2010年

3 陳曉軍;孤立性房顫患者血漿microRNA-21水平的相關研究[D];福建中醫(yī)藥大學;2015年

4 臧小彪;SNP rs3825214與中國漢族人群心房顫動關系研究[D];大連醫(yī)科大學;2012年

5 戴瑋鑫;1048例住院心房顫動病人的回顧性調查分析[D];吉林大學;2013年

本文編號：2138021